Related Experiment Video
Updated: Jan 9, 2026

Isolation and Culture of Adult Epithelial Stem Cells from Human Skin
Published on: March 31, 2011
Mesenchymal stromal cell therapy in epidermolysis bullosa: current perspectives and future directions
Twan Sia1, Rosita Primavera1, Max R Johnson1
1Center for Interventional Radiology Innovation at Stanford (IRIS), Stanford University School of Medicine, Palo Alto, CA, United States.
Abstract:
Epidermolysis bullosa (EB) is a group of inherited mucocutaneous disorders. Mesenchymal stromal cells (MSCs) are non-hematopoietic self-renewing, multipotent cells that are a promising therapeutic avenue for EB, given their ability to home to injury, low immunogenicity, and demonstrated wound-healing, anti-fibrotic, and pro-collagen effects. This review article synthesizes the current literature and advancement on MSC therapy in EB, and highlights the potential to optimize their use, including exploring MSC-derived extracellular vesicles as a potential cell-free therapy. Innovative delivery methods can also improve the accessibility and effectiveness of MSC therapies by providing localized treatment, minimizing systemic side effects, and increasing patient comfort.
More Related Videos
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Mesenchymal Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Renewal of Skin Epidermal Stem Cells
iPS Cell Differentiation

